• Rockwell Medical received Nasdaq notice dated May 8, 2026 for failing to meet minimum bid price rule 5550(a)(2) on Nasdaq Capital Market.
• Non-compliance triggered by closing bid price below USD 1 for 30 consecutive business days.
• 180-day cure period runs through Nov. 4, 2026; compliance requires bid price at or above USD 1 for 10 consecutive business days.
• Nasdaq listing continues during grace period; failure to regain compliance by deadline could open path to additional time or delisting process.
• Proxy statement includes reverse stock split proposal aimed at restoring compliance, pending stockholder support and implementation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rockwell Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-032987), on May 08, 2026, and is solely responsible for the information contained therein.